In the BioHarmony Drug Report Database

"Preview" Icon

Alitretinoin

Panretin (alitretinoin) is a small molecule pharmaceutical. Alitretinoin was first approved as Panretin on 1999-02-02. It is used to treat kaposi sarcoma and skin diseases in the USA. The pharmaceutical is active against retinoic acid receptor alpha, vitamin K epoxide reductase complex subunit 1, retinoic acid receptor beta, and retinoic acid receptor gamma. In addition, it is known to target retinoic acid receptor RXR-alpha, retinoic acid receptor RXR-gamma, retinoic acid receptor RXR-beta, and thyroid hormone receptor alpha.

 

Trade Name

 

Panretin
 

Common Name

 

alitretinoin
 

ChEMBL ID

 

CHEMBL705
 

Indication

 

kaposi sarcoma, skin diseases
 

Drug Class

 

Retinol derivatives

Image (chem structure or protein)

Alitretinoin structure rendering